Compare DLX & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DLX | RAPP |
|---|---|---|
| Founded | 1915 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | N/A | 2024 |
| Metric | DLX | RAPP |
|---|---|---|
| Price | $27.80 | $27.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $23.00 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 616.0K | 337.3K |
| Earning Date | 01-28-2026 | 03-10-2026 |
| Dividend Yield | ★ 4.32% | N/A |
| EPS Growth | ★ 58.58 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $2,133,200,000.00 | N/A |
| Revenue This Year | $1.16 | N/A |
| Revenue Next Year | $1.90 | N/A |
| P/E Ratio | $15.44 | ★ N/A |
| Revenue Growth | ★ 0.54 | N/A |
| 52 Week Low | $13.61 | $6.43 |
| 52 Week High | $28.60 | $42.27 |
| Indicator | DLX | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 71.40 | 48.33 |
| Support Level | $23.89 | $25.21 |
| Resistance Level | $28.60 | $28.59 |
| Average True Range (ATR) | 0.96 | 1.53 |
| MACD | 0.29 | 0.01 |
| Stochastic Oscillator | 92.32 | 52.96 |
Deluxe Corporation is principally a payments and data company. Its reportable segments are; Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services as well as financial institution profitability reporting and business incorporation services.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.